Upifitamab 2254118-43-7, also referred to as Mosunetuzumab, is the important step in cancer treatment field. It's an CD20 binding biologic created for selective administration of radioactive isotopes directly to malignant formations. Initial clinical findings demonstrate substantial tumoricidal e

Abelacimab, formerly known as MAA868, represents a promising approach to managing thrombosis. This blood-thinning agent is a selective monoclonal antibody that inhibits the integrin αIIbβ3, a essential player in platelet stickiness. Unlike traditional αIIbβ3 inhibitors, abelacimab demonstrates a

{Atacicept | VT-001: A Novel Therapeutic Atacicept, also known as VT-001 , represents a significant advance in therapeutic science. This unique molecule functions as a fusion molecule, effectively blocking the activity of sAPRIL, a key component in B-cell longevity and autoantibody p